CSPC Pharmaceutical Group Ltd (CHPTY) Rating Increased to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) from a sell rating to a buy rating in a report released on Tuesday. The brokerage currently has $80.00 price target on the stock.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
CSPC Pharmaceutical Group (NASDAQ CHPTY) remained flat at $73.27 during mid-day trading on Tuesday. The firm has a 50-day moving average price of $73.27 and a 200-day moving average price of $65.23. The firm has a market capitalization of $8.87 billion and a PE ratio of 31.18. CSPC Pharmaceutical Group has a 12-month low of $45.50 and a 12-month high of $73.36.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.